Epidemiological data have increasingly reported associations between several adult vaccinations and lower risk of Alzheimer disease (AD) and dementia, but the biological mechanisms that might mediate such associations remain unclear. The authors conducted an exploratory analysis to test whether adult vaccination history correlates with AD-related and immune-related biomarker profiles in cognitively unimpaired individuals at increased familial risk for AD drawn from the PREVENT-AD cohort.
The analysis included 192 participants from the PREVENT-AD study. Participants were cognitively unimpaired and selected based on familial risk for AD. Adult vaccination and infection histories were collected using a structured questionnaire. Plasma and cerebrospinal fluid (CSF) biomarkers were measured and linked to vaccination exposures for the analyses described below.
The investigators examined a principal plasma amyloid and tau biomarker panel as well as broader proteomic signatures. Adjusted regression models assessed associations for individual vaccine exposures and for the breadth of vaccination profile. Analyses also tested viral-history interactions and associations with psychological symptom measures. A false-discovery-rate (FDR) correction was applied to account for multiple testing. Where applicable, reported values follow the source results and statistical adjustments.
In adjusted models, exposures to several common adult vaccines—influenza, herpes zoster, pneumococcal, and Td/Tdap—were not associated with FDR-significant differences in the principal plasma amyloid and tau biomarker panel. Overall, the study did not identify a broad plasma amyloid or tau signature that correlated with adult vaccination history in this asymptomatic, familial-risk sample.
Within the AD biomarker panel, hepatitis B vaccination was associated with lower plasma total tau/MAPT, p-tau181, and p-tau231 after correction. The authors emphasize that these findings are hypothesis-generating and may reflect residual behavioral or healthcare-related confounding rather than a direct vaccine effect. The source notes that these associations warrant further study but does not report causal inference.
A broader vaccination profile—measuring the number or diversity of adult vaccines received—was associated with higher plasma NPTX1 (neural pentraxin 1). The reported estimate was beta = 0.261, p = 0.007, q = 0.049, indicating an association that survived FDR correction. The breadth measure had a nominal association with a lower Amyloid Beta 42/40 ratio, but that association did not remain significant after FDR correction. The authors interpret the NPTX1 finding as a potential synaptic-related signal distinct from canonical amyloid/tau pathways.
Nominal associations were observed between herpes zoster vaccination history and lower CSF Amyloid Beta 42 and pTau, but these associations were attenuated after FDR correction and did not reach robust significance. The primary CSF results therefore do not provide strong evidence of vaccination-related differences in core AD CSF biomarkers in this cohort.
Analyses testing interactions with viral history and associations with psychological symptom measures did not yield robust FDR-significant results. The source reports no other FDR-significant signals from these secondary analyses.
The study’s main conclusion is that, in this cohort of asymptomatic individuals at increased familial risk for AD, adult vaccination history was not associated with a broad plasma amyloid or tau signature. Two findings are highlighted as hypothesis-generating: the association between broader vaccination exposure and higher plasma NPTX1, which suggests a possible synaptic-related signal, and the hepatitis B–related associations with lower tau measures in plasma within the AD biomarker panel.
Limitations noted by the authors include the exploratory, cross-sectional design and the potential for residual confounding (for example, behavioral or healthcare access differences associated with vaccination). The source explicitly calls for longitudinal studies that incorporate vaccine timing, infection burden, and repeated biomarker measurements to determine whether vaccination influences biological pathways relevant to AD resilience.
The PREVENT-AD study protocols, consent forms, and procedures were approved by the McGill University Institutional Review Board and/or the Douglas Mental Health University Institute Research Ethics Board. All participants provided written informed consent. The authors declare no competing interests. Data used in the study are available upon reasonable request to the authors, subject to ethical and privacy restrictions.